Publications by authors named "Jeff P Sharman"

38Publications

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

Sci Immunol 2020 06 5;5(48). Epub 2020 Jun 5.

Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD; Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, MD; Willamette Valley Cancer Institute and Research Center, US Oncology, Eugene, OR; Hematology-Oncology Department, Walter Reed National Military Medical Center, Bethesda, MD; John Theurer Cancer Center, Hackensack Meridian and School of Medicine at Seton Hall, NJ; Rocky Mountain Cancer Center, US Oncology, Colorado Springs, CO; Department of Emergency Medicine, Penrose-St. Francis Health Services, Colorado Springs, CO; US Acute Care Solutions, Canton, OH; Department of Medicine, St. Peter's Hospital and US Oncology, Albany, NY; Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD; Acerta Pharma, South San Francisco, CA; Biometric Research Branch, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD, USA AstraZeneca, One MedImmune Way, Gaithersburg, MD

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/sciimmunol.abd0110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274761PMC
June 2020

Targeting CD20: teaching an old dog new tricks.

Authors:
Jeff P Sharman

Hematology Am Soc Hematol Educ Program 2019 12;2019(1):273-278

Willamette Valley Cancer Institute/US Oncology, Eugene, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/hematology.2019000031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913507PMC
December 2019

Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.

Curr Oncol Rep 2018 04 11;20(6):49. Epub 2018 Apr 11.

Williamette Valley Cancer Institute and Research Center, Eugene, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0694-xDOI Listing
April 2018

Ibrutinib for Chronic Lymphocytic Leukemia.

N Engl J Med 2016 04;374(16):1592-3

University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1600328DOI Listing
April 2016

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Blood 2014 May 20;123(20):3095-100. Epub 2014 Mar 20.

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-12-542142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425442PMC
May 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365PMC
March 2014

Effectiveness of warfarin among patients with cancer.

J Gen Intern Med 2007 Jul 3;22(7):997-1002. Epub 2007 May 3.

Department of Medicine, Research Unit-Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118-2644, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11606-007-0228-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219727PMC
July 2007

Gemcitabine-associated thrombotic microangiopathy.

Cancer 2004 Jun;100(12):2664-70

Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20290DOI Listing
June 2004